Should you go for GlaxoSmithKline (GSK) share after solid Q1 results?

Be the First to Comment Read

Should you go for GlaxoSmithKline (GSK) share after solid Q1 results?

 Should you go for GlaxoSmithKline (GSK) share after solid Q1 results?
Image source: Tyler Olson, Shutterstock.com

Highlights

  • GlaxoSmithKline Plc announced its Q1 2022 results on Wednesday and surpassed expectations with a turnover of £9.8 billion.
  • The growth was led by the strong sales of GSK's COVID-19 drug Xevudy as the company generated £1.3 billion in sales from it.

British drugmaker GlaxoSmithKline Plc (LON: GSK) on Wednesday announced the results for the first quarter of 2022, surpassing the expectations with a strong performance. Shares of the company gained over 2% during the day following the announcement.

The FTSE 100-listed company reported strong growth in sales across its Biopharma and Consumer Healthcare business, which is set to become an independent entity post its demerger in mid-2022. Its turnover for the three months to 31 March 2022 surged by 32% to settle at £9.8 billion, and the profit before tax reached £2.6 billion, 71% more than the corresponding period in the previous year.

Key performers

The growth was led by the strong sales of GSK's COVID-19 drug Xevudy as the company generated £1.3 billion in sales from its medicine used for treating the infection. On the other hand, the shingles vaccine Shingrix fetched close to £700 million in sales. The duo took the total sales for speciality medicines during the quarter to £3.1 billion. The sale of general medicines stood at £2.3 billion.

© 2022 Kalkine Media®

Region-wise, the US contributed the most to the sales at £3.5billion, followed by other countries at £1.9 billion and Europe at £1.6 billion.

Outlook

For this year, the company expects the sales growth to stay between 5% to 7% and a 12-14% growth in the adjusted operating profit as compared to 2021. Notably, the forecast does not include the sales of Xevudy and other COVID-related products.

Performance of GSK's stock

The Brentford-headquartered company is the UK's second-largest drugmaker and manufactures a range of drugs, vaccines, and consumer healthcare products. It is a constituent of the blue-chip FTSE 100 index.

During the COVID-19 pandemic, GSK's investors got good returns from the stock, and the price has appreciated by 33.42% over the last one year as of 27 April 2022. So far this year, it has performed decently with a year-to-date return of 11.24%.

GlaxoSmithKline’s shares closed at GBX 1,797.00 on 27 April 2022. The drugmaker's current market cap stands at £91,357.65 million.

Note: The above content constitutes a very preliminary observation or view based on industry trends and is of limited scope without any in-depth fundamental valuation or technical analysis. Any interest in stocks or sectors should be thoroughly evaluated taking into consideration the associated risks.

--------------------------------------------------------------------------------------------------

Sources:

https://www.gsk.com/media/7639/q1-2022-announcement.pdf

https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-tops-quarterly-expectations-consumer-arm-spin-off-track-2022-04-27/

https://uk.finance.yahoo.com/news/gsk-beats-forecasts-after-covid-treatment-boost-112202058.html

Disclaimer

Speak your Mind

Featured Articles